This Week in Neurology — May 14, 2026

Welcome to This Week in Neurology. This week we're covering 10 notable papers spanning advances in acute stroke treatment, new insights into diagnosing and predicting neurodegenerative diseases, and a look at foundational science shaping the future of neurology. Let's dive in.

We start this week in acute stroke, with two major papers addressing key clinical questions in thrombolysis and thrombectomy. The first, from The New England Journal of Medicine, expands the population eligible for mechanical thrombectomy.

The Study

This was the ORIENTAL-MeVO trial, an open-label, randomized trial conducted at 48 centers in China [9]. It enrolled adult patients with a moderate-to-severe acute ischemic stroke, defined as an NIH Stroke Scale score of 6 or higher, caused by a medium-vessel occlusion, or MeVO. Patients presenting within 24 hours of onset were randomized to either thrombectomy plus standard medical management or medical management alone. The primary outcome was functional independence, defined as a modified Rankin Scale score of 0 to 2, at 90 days.

Results

The trial included 563 patients. At 90 days, functional independence was achieved by 58.6% of patients in the thrombectomy group, compared to 46.6% in the medical management group. This represented a statistically significant improvement, with an adjusted rate ratio of 1.24. On the safety side, thrombectomy was associated with a higher incidence of symptomatic intracranial hemorrhage, occurring in 4.7% of the thrombectomy group versus 2.2% of the control group. However, there was no significant difference in 90-day mortality between the two groups.

Conclusions

For patients with acute ischemic stroke due to a medium-vessel occlusion and moderate-to-severe deficits, this trial provides strong evidence that thrombectomy leads to a greater likelihood of functional independence compared to medical management alone. This finding helps clarify the benefit of thrombectomy in this specific patient population, where previous trial results have been mixed, and will likely expand the indication for intervention.

While thrombectomy expands, another study in *Neurology* tackles a common barrier to intravenous thrombolysis: the use of direct oral anticoagulants [3]. Specifically, it addresses the safety of giving IVT after reversing dabigatran with idarucizumab.

The Study

This was an observational study using data from the large, international SITS stroke registry. The investigators identified patients with acute ischemic stroke who were on dabigatran and received idarucizumab for reversal immediately prior to receiving IVT. Using propensity score matching, they compared the outcomes of these patients to a control group of patients who received IVT but had no prior history of oral anticoagulant use.

Results

After matching, the analysis showed no significant differences in key safety or efficacy outcomes. The rate of any parenchymal hematoma was 3% in the dabigatran reversal group versus 9% in the control group, a non-significant difference. Rates of symptomatic intracranial hemorrhage were identical at 1% in both groups. There were also no differences in 3-month mortality or functional independence. The authors note this provides Class III evidence for the practice.

Conclusions

In this large observational registry, treating acute ischemic stroke with IVT after reversing dabigatran with idarucizumab appeared to be as safe and effective as giving IVT to patients not on anticoagulation. For clinicians facing this scenario, these data provide reassurance that this strategy does not appear to increase hemorrhagic risk or worsen outcomes.

Next, we turn to neurodegenerative disorders, where four new papers explore how to better diagnose and predict outcomes, using a mix of clinical signs and biomarkers.

A paper in the *Annals of Neurology* revisits the diagnostic and prognostic power of a classic clinical sign: the long-duration levodopa response in parkinsonian syndromes [1].

The Study

The investigators analyzed medical records from hundreds of patients with pathology-confirmed Parkinson's disease (PD), multiple system atrophy (MSA), and progressive supranuclear palsy (PSP). They specifically looked for a "definite" levodopa response, which they defined as a motor improvement of greater than 50% that was sustained for more than two years.

Results

A definite levodopa response was highly specific to Parkinson's disease. It was present in 86% of patients with PD, but in only 8% of those with MSA and just 2% of those with PSP. This gave it excellent diagnostic accuracy for distinguishing PD from these atypical parkinsonian syndromes, with a sensitivity of 86% and a specificity of nearly 96%. Furthermore, within the PD group, having a definite response carried significant prognostic weight. PD patients who were definite responders had a 55% lower risk of falls, a 69% lower risk of dementia, and a 69% increase in survival compared to PD patients without such a response. The authors also note that the response to a short-duration, acute levodopa challenge was not nearly as useful for diagnosis.

While that study refines diagnosis in established disease, another paper in the *Annals of Neurology* looks even earlier, at identifying individuals *before* a Parkinson's diagnosis is made [5]. This paper reviews the strategies used by the Parkinson's Progression Markers Initiative, or PPMI, to enroll at-risk individuals. The key lesson is the power of combining clinical signs with fluid biomarkers. The review highlights that severe hyposmia remains the single strongest clinical predictor of an underlying synucleinopathy. This is now being confirmed by cerebrospinal fluid alpha-synuclein seed amplification assays, or aSyn SAA. Critically, the study notes that the CSF biomarker becomes positive *before* dopamine transporter deficits are visible on imaging, allowing for the identification of individuals in the earliest biological stages of the disease. This biomarker-driven approach is essential for designing future clinical trials aimed at neuroprotection.

Moving from synucleinopathies to diseases linked with amyloid and tau, a study in *Neurology* investigates how to best predict dementia risk in people with only subjective cognitive decline [4].

The Study

This longitudinal study followed 469 individuals with subjective cognitive decline from two large European cohorts. The researchers evaluated a range of potential predictors, including cognitive scores, APOE4 status, MRI measures of atrophy and white matter disease, and a plasma biomarker, phosphorylated tau 217, or p-tau217.

Results

Over a follow-up of about four years, 84 individuals progressed to dementia. The single strongest individual predictor of progression to Alzheimer's disease dementia was the plasma p-tau217 level, which achieved a C-index of 0.86. However, multimodal models performed even better. The best model for predicting progression to Alzheimer's dementia combined plasma p-tau217, cognitive scores, and APOE4 status. This relatively simple, clinically feasible model achieved an excellent predictive ability with a C-index of 0.91. Adding MRI markers of brain atrophy and white matter hyperintensities provided only marginal additional improvement for predicting AD dementia specifically, though it did improve prediction for all-cause dementia.

Conclusions

This study underscores the immense clinical value of plasma p-tau217. It suggests that a combination of a blood test, genetic screening, and standard cognitive testing can very accurately stratify the risk of future Alzheimer's dementia in patients presenting to memory clinics with subjective complaints.

But while biomarkers are sharpening our view of Alzheimer's and Parkinson's disease, a sobering report in *Nature Medicine* shows that our clinical tools for another neurodegenerative disease, chronic traumatic encephalopathy, are falling far short [2].

The Study

Researchers sought to validate the consensus diagnostic criteria for the clinical syndrome associated with CTE, known as traumatic encephalopathy syndrome, or TES. They reviewed antemortem clinical records for over 1,000 individuals from a neurodegenerative brain bank and then performed postmortem neuropathological evaluation for CTE on all of them.

Results

The performance of the TES criteria was poor. Only 25 cases in the entire cohort met the clinical criteria for TES. Of those 25 individuals diagnosed clinically, only 6 actually had CTE pathology at autopsy. This translates to a positive predictive value of just 24%. The analysis revealed that what drove the clinical diagnosis was almost entirely the history of exposure to repetitive head impacts, rather than the specific core or supportive clinical features proposed in the criteria. In fact, there was no difference in the prevalence of those clinical features between cases with and without CTE pathology.

Conclusions

This study raises substantial concerns about the current clinical criteria for TES. The poor diagnostic accuracy creates a high risk of misdiagnosing current and former athletes with a progressive neurodegenerative disease they do not have, potentially causing significant psychological harm. It highlights a critical need to develop more specific clinical criteria and validated biomarkers for CTE.

Finally, we'll look at four papers that lay the groundwork for future understanding and treatment, from basic neuroscience to novel therapeutics.

In *Science Translational Medicine*, researchers report a major step forward for a potential treatment for Dravet syndrome, a severe neurodevelopmental epilepsy [10].

The Study

They used a gene editing technology called an adenine base editor, or ABE, delivered via dual adeno-associated viruses, to directly correct a recurrent disease-causing variant in the SCN1A gene. They tested this strategy in a mouse model that recapitulates key features of Dravet syndrome.

Results

When administered to neonatal mice, the AAV-base editor treatment was highly efficient, resulting in 59% DNA correction and 97% mRNA correction in the neocortex. This genetic repair restored the function of inhibitory neurons, ameliorated both spontaneous and temperature-induced seizures, and led to a dramatic improvement in survival. At 45 days, 90% of the treated mice were alive, compared to just 27% of vehicle-treated mice. Importantly, a survival benefit was also seen when the treatment was administered to older, 12-day-old mice. This work provides a powerful proof-of-concept for using precision genome editing to treat the root cause of Dravet syndrome.

Shifting to vascular dementia, a pre-clinical study in *Stroke* identifies a potential therapeutic target for protecting white matter from chronic hypoperfusion [6]. The study focused on adiponectin, the most abundant hormone secreted by fat cells. In mouse models of vascular cognitive impairment, the researchers found that a lack of adiponectin worsened white matter lesions. Conversely, administering a small-molecule drug that activates adiponectin receptors improved white matter integrity and cognitive function. The mechanism appears to involve both directly protecting myelin-producing oligodendrocytes and promoting a reparative phenotype in microglia, which helps clear away damaged myelin debris. This work nominates the adiponectin pathway as a novel therapeutic target for vascular cognitive impairment.

And finally, two papers in *Nature* this week provide fundamental new resources for the neuroscience community. First, a team has created the first-ever lifespan reference charts for the brain's white matter [8]. By processing and standardizing over 35,000 brain scans from individuals from birth to 100 years of age, they have mapped the typical growth, maturation, and age-related decline of specific brain pathways. Much like pediatric growth charts, these normative references will allow clinicians and researchers to quantify how an individual's brain connectivity deviates from the typical pattern, providing a benchmark for studying development, aging, and a wide range of neurological disorders.

The second *Nature* paper delves into the genetic programs that drive brain evolution [7]. Using machine vision to compare gene expression in the developing neocortex of mice and humans, researchers identified key differences in the timing and location of shared genes. They focused on a transcription factor called JUNB, which was expressed in progenitors in humans but in neurons in mice. Through elegant gain- and loss-of-function experiments in mouse models and human cortical organoids, they showed that they could bidirectionally control human-like cortical features, such as progenitor proliferation rates and neuronal output, simply by manipulating JUNB. This work provides a molecular framework for understanding how subtle evolutionary changes in gene regulation can lead to profound differences in brain structure and function between species.

If you only have time for one paper this week, make it the ORIENTAL-MeVO trial in *The New England Journal of Medicine* [9]. This trial provides clear evidence supporting thrombectomy for medium-vessel occlusion strokes with moderate-to-severe deficits, a patient group where benefit was previously uncertain. This result is likely to expand the indication for thrombectomy and change practice for many stroke centers.

Here are the key takeaways from this week in Neurology.

First, in acute stroke, endovascular thrombectomy is beneficial for patients with moderate-to-severe deficits from medium-vessel occlusions [9]. And for patients on dabigatran, IV thrombolysis after reversal with idarucizumab appears safe [3].

Second, in movement disorders, a sustained, long-duration response to levodopa remains a powerful tool, not only for diagnosing Parkinson's disease but also for predicting a more favorable prognosis with lower risks of falls, dementia, and death [1].

Third, for patients with subjective cognitive decline, a combination of a blood test—plasma p-tau217—along with cognitive testing and APOE4 status can very accurately predict the risk of progressing to Alzheimer's dementia, highlighting a clinically feasible pathway for early risk stratification [4].

Finally, a word of caution: the current clinical criteria for traumatic encephalopathy syndrome have a very low positive predictive value for underlying CTE pathology, and a diagnosis should be made with extreme care given the risk of psychological harm from a misdiagnosis [2].

That's your roundup for This Week in Neurology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.